HOTLINE: Effective August 16, 2021

New Test **3004094** **Rivaroxaban Level** **RIVAROX**

Methodology: Chromogenic Assay
Performed: Tuesday
Reported: 1-8 days

Specimen Required: Collect: Lt. blue (sodium citrate). Refer to Specimen Handling at aruplab.com for hemostasis/thrombosis specimen handling guidelines.
Specimen Preparation: Transport 2 mL platelet-poor plasma. (Min: 1 mL)
Storage/Transport Temperature: CRITICAL FROZEN. Separate specimens must be submitted when additional tests are ordered.
Remarks: This test cannot be used to quantitate anticoagulants other than Rivaroxaban. This includes but is not limited to Unfractionated Heparin, Low Molecular Weight Heparin, Apixaban (Eliquis), Edoxaban (Savaysa), and Fondaparinux (Arixtra).
Unacceptable Conditions: Serum. EDTA, oxalate, heparin, or plasma separator tubes, hemolyzed specimens.
Stability (collection to initiation of testing): After separation from cells: Ambient: 4 hours; Refrigerated: Unacceptable; Frozen: 1 month

Reference Interval: Not established

Interpretive Data:
When 20 mg rivaroxaban was administered daily for treatment of DVT and PE, rivaroxaban steady state levels were as follows:
Peak: 189-419 ng/mL
Trough: 6-87 ng/mL
The lower limit of detection for this assay is 25 ng/mL.
For additional information, please refer to www.arupconsult.com

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

CPT Code(s): 80299

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.